EXCLUSIVE: HemoGenyx are creating blood cancer treatments with US$9 billion market potential

#HEMO are a London-listed, US-based biotech company developing two revolutionary blood cancer treatments.

CDX antibodies are intended to remove the need for chemo and radiation before a bone marrow transplant is done. The potential market for this treatment is worth $8/9 billion annually.
Lake Pharma have been signed-up to create antibodies for the clinical trial phase which will take place ‘within 16 months’.

Hu-PHECS are Hemo’s second product candidate, and CEO and co-Founder Dr Vladislav Sandler hopes their recent academic collaboration with Oxford University will create ‘a new opportunity’ for his company. The new treatment will turn dormant blood cells into active ones, ready for a bone marrow transplant and does away with the requirement to find a matching donor. 40% of people currently can’t find a donor. This product is 24 to 36 months from clinical trials.

Both treatments have achieved proof of principle status.


Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.